Mostrando ítems 1-5 de 5
Advances in hepatitis B therapeutics
(Therapeutic Advances in Infectious Disease, 2020-10)
Despite the availability of both effective preventive vaccines and oral antivirals, over 250 million people are chronically infected with the hepatitis B virus (HBV). Globally, chronic hepatitis B is the leading cause of ...
Overt and occult hepatitis B among immigrants and native blood donors in Madrid, Spain
(Therapeutic Advances in Infectious Disease, 2020-12)
Background: The risk of transfusion-transmitted viral infections is very low in developed countries. Recent massive migration flows from highly hepatitis B virus (HBV), hepatitis C virus (HCV) and/or HIV endemic regions ...
Why such excess of mortality for COVID-19 in Spain?
(Therapeutic Advances in Infectious Disease, 2020-06)
The current global crisis produced by the SARS-CoV-2 pandemic is unprecedented. Even the 1918 influenza pandemic (Spanish flu) did not halt the planet so abruptly and deeply as it ran during World War I.
Keeping alive enterprises while embracing unprecedented COVID-19 restrictions
(Therapeutic Advances in Infectious Disease, 2020-04)
COVID-19 is rapidly expanding globally, with more than 1,800,000 cases and 105,000 deaths to date (April 11, 2020) (www.worldometers.info). The WHO upgrade to pandemic, the emergency declaration in the United States, and ...
Hepatitis C Treatment Outcomes in Persons With HIV and Decompensated Cirrhosis Using a Collaborative Multidisciplinary HIV-Centered Approach
(SAGE Publications Inc., 2021)
Fifty-four consecutive persons with HIV co-infected with hepatitis C virus (HCV) and liver decompensation were treated with direct-acting antivirals (DAA). The HCV treatment was delivered using a multidisciplinary ...